The increase in dose when patients transferred from analogue basal insulin to BIAsp 30 did not, however, have corollaries in terms of hypoglycaemia; the rates of major and minor hypoglycaemia were reduced following BIAsp 30 therapy compared with rates on analogue basal insulin (major: 1.1–0.03, p < 0.05; minor: 2.9–2.2 episodes/patient/year, not statistically significant, p>0.05) (10). Here, INS is linked to Hypoglycemia.